Thursday 16 October, 2025
Introduction/Objectives: Amyloidosis is a rare fatal disease caused by progressive extracellular deposition of amyloid fibrils which damage tissue structure and function[1]….
Read morePoster: Other Drug/Disease Modelling
First-order longitudinal population model of FEV1 data: single-trial modeling and meta-analysis
Thursday 16 October, 2025
Objectives: Asthma is a complex and multi-factorial disease and the underlying physiopathological mechanism is not completely known. Therefore, empirical models…
Read morePopulation pharmacokinetics of cyclosporine A in cats
Thursday 16 October, 2025
Objectives: To evaluate the pharmacokinetics of cyclosporine A (CsA) in healthy cats following single dose administration and to explore the…
Read moreShort- and Long-Term Effects of Tocilizumab on Neutrophil Counts in Pediatric Patients with Systemic Juvenile Idiopathic Arthritis
Thursday 16 October, 2025
Objectives: Tocilizumab (TCZ) is a recombinant humanized IL-6 receptor monoclonal antibody that inhibits binding of IL-6 to its receptors. The…
Read moreDosage individulisation of tacroliums in adult kidney transplant recipients
Thursday 16 October, 2025
Objectives: 1) To develop a population pharmacokinetic model of tacrolimus in adult kidney transplant recipients; 2) to use this model…
Read morePopulation PK/PD analysis linking the direct acute effects of canagliflozin on renal glucose reabsorption to the overall effects of canagliflozin on long-term glucose control using HbA1c as the response marker from clinical studies
Thursday 16 October, 2025
Objectives: Canagliflozin is an orally active inhibitor of SGLT2, currently in development for the treatment of patients with T2DM. A…
Read morePK-PD modelling of aOSM in RA patient study including exploration of carrier protein effect.
Thursday 16 October, 2025
Objectives: A humanised IgG1 monoclonal antibody (mAb) against human Oncostatin M (OSM) has been recently developed for the treatment of…
Read moreA population PK-PD model for effects of Sipoglitazar on FPG and HbA1c in patients with type II diabetes.
Thursday 16 October, 2025
Objectives: Sipoglitazar is a PPAR γ, α & δ agonist for treating type 2 diabetes mellitus (T2DM) by improving insulin…
Read moreA mechanistic model for the involvement of the neonatal Fc receptor in IgG disposition
Thursday 16 October, 2025
Objectives: One of the recognised functions of the neonatal Fc receptor (FcRn) is to protect IgG from catabolism by endosomal…
Read moreA closed-form solution set-point model of treatment response in multiple diseases
Thursday 16 October, 2025
Objectives: Many clinical trials demonstrate a profound placebo response once patients enter the trial, which may invalidate interpretation of trial…
Read more